Pyruvate kinase type tumor M2 in urological malignancies

Urologia Internationalis

Volumn 70, Issue 1, 2003, Pages 55-58

  Hegele, Axel ^a,b   Varga, Z ^a   Kosche, B ^a   Stief, T ^a   Heidenreich, A ^a   Hofmann, R ^a  

^a Fachbereich Medizin der Universitat Marburg   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Pyruvate kinase; Tumor marker; Urological tumors

Indexed keywords

ISOENZYME; PYRUVATE KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; PYRUVATE KINASE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 0037261207     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067707     Document Type: Article

References (15)

1. Nicol D, Hii SI, Walsh M, Teh B, Thompson L, Kennett C, Gotley D: Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 1997;157:1482-1486.
2. 1 in patients with renal cell carcinoma. Eur Urol 2001; 39(suppl 5):54.
3. Zaher A, Sheridan T: Tumor markers in the detection of recurrent transitional cell carcinoma of the bladder: A brief review. Acta Cytol 2001;45:575-581.
4. Cassel A, Rahat MA, Lahat N, Lindenfeld N, Mecz Y, Stein A: Telomerase activity and cytokeratin 20 as markers for the detection and follow-up of transitional cell carcinoma: An unfulfilled promise. J Urol 2001;166:841-844.
5. Ibsen KH, Orlando RA, Garrat KN, Hernandez AN, Giorlando S, Nungaray G: Expression of multimolecular forms of pyruvate kinase in normal, benign and malignant human breast tissue. Cancer Res 1982;42:888-892.
6. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R: Double role for pyruvate kinase type M2 in expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog 1992;3:91-115.
7. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G: Quantification of tumor type M2 pyruvate kinase (TuM2-PK) in human carcinomas. Anticancer Res 1997;17:3153-3156.
8. Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E: Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 2000;24:531-535.
9. Wechsel HW, Petri E, Bichler KH, Feil G: Marker for renal cell carcinoma: The dimeric form of pyruvate kinase type M2 (TuM2-PK). Anticancer Res 1999;19:2583-2590.
10. Hugo F, Fischer G, Eigenbrodt E: Quantitative detection of tumor M2-PK in serum and plasma. Anticancer Res 1999;19:2753-2757.
11. Oremek GM, Sapoutzis N, Kramer W, Bickeböller R, Jonas D: Value of tumor M2 (TuM2-PK) in patients with renal carcinoma. Anticancer Res 2001;20:5095-5098.
12. Cerwenka H, Aigner R, Bacher H, Werkgartner G, El-Shabrawi A, Quehenberger F, Mischinger HJ: TuM2-PK (pyruvate kinase type tumor M2), CA 19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res 1999;19:849-851.
13. Sobin LH, Wittekind C (eds): TNM Classification of Malignant Tumors, ed 5. New York, Wiley, 1997.
14. Mazurek S, Scheefers-Borchel U, Scheefers H, Michel A, Basenau D, Fischer G, Dahlmann N, Laumen R, Eigenbrodt E: Die Bedeutung der Pyruvatkinase in der Onkologie. Notabene Med 1993;3:97-103.
15. Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA: Tumor M2 pyruvate kinase in plasma of patients with urological tumors. Tumor Biol 2001;22:282-285.